Myriad Genetics, Inc. (MYGN) vs Rezolute, Inc. (RZLT)
A side-by-side comparison of Myriad Genetics, Inc. and Rezolute, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MYGN
Myriad Genetics, Inc.
$4.38HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
RZLT
Rezolute, Inc.
$4.34HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — MYGN vs RZLT
growth of $100 · dividends reinvested · last 10yMYGN -77.8% (-14.0%/yr)RZLT -94.6% (-25.3%/yr)MYGN compounded faster over this window
MYGN RZLT
MYGN vs RZLT: by the numbers
- •RZLT is the larger company ($418M vs $413M market cap).
- •Both run net losses; RZLT's is the smaller (0.00% vs -13.96% net margin).
Metrics side by side
Valuation
| Metric | MYGN | RZLT |
|---|---|---|
| P/S ratio | 0.51 | N/A |
| P/B ratio | 1.36 | 4.15 |
Profitability
| Metric | MYGN | RZLT |
|---|---|---|
| Gross margin | 68.83% | 0.00% |
| Operating margin | -12.22% | 0.00% |
| Net margin | -13.96% | 0.00% |
| ROE | -37.05% | -77.06% |
| ROIC | -19.13% | -81.80% |
Growth (annualized)
| Metric | MYGN | RZLT |
|---|---|---|
| Revenue CAGR (5Y) | 9.70% | N/A |
| Total return CAGR (5Y) | -32.02% | -9.57% |
Frequently asked
- How have MYGN and RZLT total returns compared?
- Over the past 10 years, MYGN delivered -14.20% and RZLT delivered -25.30% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.